T1	Outcomes 290 308	cell proliferation
T2	Outcomes 313 322	survival.
T3	Outcomes 397 405	efficacy
T4	Outcomes 410 416	safety
T5	Outcomes 1226 1258	median progression-free survival
T6	Outcomes 1309 1325	overall survival
T7	Outcomes 1537 1569	Median progression-free survival
T8	Outcomes 1751 1752	.
T9	Outcomes 1753 1769	However, overall
T10	Outcomes 1992 2027	grade 3 or higher adverse event was
T11	Outcomes 2126 2140	placebo group.
T12	Outcomes 2141 2155	Hyperglycaemia
T13	Outcomes 2297 2311	placebo group.
T14	Outcomes 2312 2327	Serious adverse
T15	Outcomes 2616 2631	did not improve
